This discussion is locked.
You cannot post a reply to this discussion. If you have a question start a new discussion

Symptomatic Similarity of Coronavirus Disease and the Pneumonia

Former Community Member
Former Community Member

Symptomatically, the Coronavirus Disease is very similar to that Pneumonia. Also, Pneumonia has been known to cause havoc around the Indo-China region historically. Today, there is a medical cure in prevention by using Vaccines against the Pneumonia virus. Consequently, it seems that the Coronavirus is a severe form of the Pneumonia, in that it has a higher fatality rate. However, it can be reasonably assured that such severity could be due to environmental causes at the source of origin. In other Non-Source countries where the disease is transmitted, would not have such an environmental risk, rather a risk of transmission by human contact and air droplets. Hence, it could be inferred that taking appropriate precautions against the Pneumonia would prevent the higher risk of the disease at transmitted countries. Accordingly, WHO should recommend the Pneumonia Vaccine as a Primary Precaution, whilst further development and testing is carried out comprehensively for the Coronavirus itself. Post majority implementation of the Primary Precaution, a higher transmission rate and lockdowns could be avoided. Non-Source countries should target to maintain 70% Vaccination rate on an ongoing basis.

 

www.healthdirect.gov.au/pneumonia

Parents
  • Former Community Member
    0 Former Community Member

    Suggesting that “Big Pharma” is not interested in antivirals for SARS-CoV-2 is just not correct. Regeneron has a cocktail. Eli Lilly has one. Any “Big Pharma” company would love to sell one to those many millions of people who would benefit, if they had one and could produce it in quantity. 

    Invermectin may be promising in vitro, but there are few practical studies. Here is one: 

    https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00239-X/fulltext

    This is from a couple weeks ago, only involved 45 enrollees, very moderate results. The authors' interpretation: “well tolerated”; nothing about obvious improvement. Anything that looks as if it might work will at some point be looked at in the RECOVERY trial. 

Reply
  • Former Community Member
    0 Former Community Member

    Suggesting that “Big Pharma” is not interested in antivirals for SARS-CoV-2 is just not correct. Regeneron has a cocktail. Eli Lilly has one. Any “Big Pharma” company would love to sell one to those many millions of people who would benefit, if they had one and could produce it in quantity. 

    Invermectin may be promising in vitro, but there are few practical studies. Here is one: 

    https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00239-X/fulltext

    This is from a couple weeks ago, only involved 45 enrollees, very moderate results. The authors' interpretation: “well tolerated”; nothing about obvious improvement. Anything that looks as if it might work will at some point be looked at in the RECOVERY trial. 

Children
No Data